AAAAAA
Results: 26-36/36
Authors:
Carlsson, A
Citation: A. Carlsson, Birth of neuropsychopharmacology - impact on brain research, BRAIN RES B, 50(5-6), 1999, pp. 363-363
Authors:
Carlsson, ML
Martin, P
Nilsson, M
Sorensen, SM
Carlsson, A
Waters, S
Waters, N
Citation: Ml. Carlsson et al., The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist than dopamine agonist induced hyperactivity in mice, J NEURAL TR, 106(2), 1999, pp. 123-129
Authors:
Carlsson, A
Citation: A. Carlsson, Network entrepreneurs: History of technological research and industrial development from the Swedish Council for Technical Research to the National Board for Technical Development, TECHNOL CUL, 40(2), 1999, pp. 397-399
Authors:
Lindberg, B
Ahlfors, K
Carlsson, A
Ericsson, UB
Landin-Olsson, M
Lernmark, A
Ludvigsson, J
Sundkvist, G
Ivarsson, SA
Citation: B. Lindberg et al., Previous exposure to measles, mumps, and rubella - But not vaccination during adolescence - Correlates to the prevalence of pancreatic and thyroid autoantibodies, PEDIATRICS, 104(1), 1999, pp. E121-E125
Authors:
Ekesbo, A
Torstenson, R
Hartvig, P
Carlsson, A
Sonesson, C
Waters, N
Tedroff, J
Langstrom, B
Citation: A. Ekesbo et al., Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements of [C-11]SCH23390 and [C-11]raclopride binding in primate brains, NEUROPHARM, 38(3), 1999, pp. 331-338
Authors:
Tedroff, J
Ekesbo, A
Sonesson, C
Waters, N
Carlsson, A
Citation: J. Tedroff et al., Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease, NEUROLOGY, 53(7), 1999, pp. 1605-1606
Authors:
Carlsson, A
Kaneda, M
Sakamoto, Y
Terasaki, O
Ryoo, R
Joo, SH
Citation: A. Carlsson et al., The structure of MCM-48 determined by electron crystallography, J ELEC MICR, 48(6), 1999, pp. 795-798
Authors:
Tuomi, T
Carlsson, A
Li, HY
Isomaa, B
Miettinen, A
Nilsson, A
Nissen, M
Ehrnstrom, BO
Forsen, B
Snickars, B
Lahti, K
Forsblom, C
Saloranta, C
Taskinen, MR
Groop, LC
Citation: T. Tuomi et al., Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies, DIABETES, 48(1), 1999, pp. 150-157
Authors:
Carlsson, A
Hansson, LO
Waters, N
Carlsson, ML
Citation: A. Carlsson et al., A glutamatergic deficiency model of schizophrenia, BR J PSYCHI, 174, 1999, pp. 2-6
Authors:
Carlsson, A
Waters, N
Carlsson, ML
Citation: A. Carlsson et al., Neurotransmitter interactions in schizophrenia - Therarpeutic implications, BIOL PSYCHI, 46(10), 1999, pp. 1388-1395
Authors:
Gustafsson, O
Mansour, E
Norming, U
Carlsson, A
Tornblom, M
Nyman, CR
Citation: O. Gustafsson et al., Prostate-specific antigen (PSA), PSA density and age-adjusted PSA reference values in screening for prostate cancer - A study of a randomly selected population of 2,400 men, SC J UROL N, 32(6), 1998, pp. 373-377